Related Articles
Pegylated liposomal doxorubicin: Pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (Review)
Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors
Non‑pegylated liposomal doxorubicin for patients with recurrent ovarian cancer: A multicentric phase II trial
Weekly pegylated liposomal doxorubicin and paclitaxel in patients with metastatic breast carcinoma: A phase II study
Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy.